In a mouse model of IgAN, the administration of a neutralizing-antibody targeting APRIL resulted in the suppression of glomerular IgA deposition and improved nephropathy, underscoring the significance of APRIL in disease progression [69,70]. Here, TNFSF13 is linked to kidney disorder.